$3.25
−0.91%Price chart
Sep 24Sep 29Oct 2Oct 7Oct 12Oct 15Oct 20Oct 23
Key dataOct 23, 2026
Open$3.28
From 52W high−61.72%
Volume6368.00
Market cap$18.61M
P/E (TTM)—
P/S (TTM)138.7x
Div yield—
Key dataOct 23, 2026
Open
$3.28
From 52W high
−61.72%
Volume
6368.00
Market cap
$18.61M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−3.0x
P/E (TTM)
—
RSI (14)
29.5
MomentumView details →
1D Return
−0.91%
YTD Return
−52.41%
Similar companies
Latest newsMore news →
Optimi Health Corp. completed and quality-released a production batch of 5mg naturally derived psilocybin capsules at its cGMP facility in Princeton, British Columbia, to supply a Health Canada-approved Phase 2 MDD trial and commercial customers in Australia.30d agoOptimi Health expanded its clinical program with a Health Canada-authorized Phase 3 trial evaluating MDMA-assisted therapy for post-traumatic stress disorder in up to 100 veterans and frontline workers.37d agoOptimi Health announced it will initiate a Phase 2 clinical trial evaluating psilocybin-assisted therapy for major depressive disorder, authorized by Health Canada, with dosing expected to be completed by the end of 2027.43d ago